Immunocore Holdings PLC has unveiled its strategic priorities for 2025, including plans to expand access to its Kimmtrak (tebentafusp) drug for metastatic uveal melanoma patients in more countries. The company has made Kimmtrak available in 23 countries and aims to reach more patients globally through additional launches and approvals.
The company has also revealed that it is enrolling patients in three registrational phase 3 trials for its melanoma franchise. The first topline results are anticipated in 2026, with the potential to reach up to 15,000 additional patients across three new melanoma indications.
In addition to its focus on melanoma, Immunocore is advancing its clinical portfolio by enrolling patients in multiple phase 1 oncology trials with brenetafusp, imc-p115c, imc-r117c, and imc-m113v in HIV. The company aims to present initial data from the HIV phase 1 trial in the first quarter of 2025.
Furthermore, Immunocore is innovating for sustainable growth by planning to submit a clinical trial application for its autoimmune disease candidates, imc-s118ai and imc-u120ai, by the end of 2025 and in 2026, respectively.
The company's preliminary unaudited cash, cash equivalents, and marketable securities were approximately $820 million as of December 31, 2024. Immunocore will report its final fourth-quarter and full-year 2024 financial results in late February 2025.
Immunocore's management is scheduled to discuss these updates during a live presentation at the 43rd annual J.P. Morgan Healthcare Conference on January 15, 2025.
The company's strategic priorities for 2025 demonstrate its commitment to expanding patient access to its treatments, advancing its clinical portfolio, and innovating for sustainable growth in the biotechnology sector. As a result of these announcements, the company's shares have moved 0.6% on the market, and are now trading at a price of $30.4. Check out the company's full 8-K submission here.
